Literature DB >> 25916253

Withstanding the obstructive sleep apnea syndrome at the expense of arousal instability, altered cerebral autoregulation and neurocognitive decline.

Mohammad Torabi-Nami1,2,3, Samrad Mehrabi2,4, Afshin Borhani-Haghighi1,5, Sabri Derman6.   

Abstract

The present review attempts to put together the available evidence and potential research paradigms at the interface of obstructive sleep apnea syndrome (OSAS), sleep micro- and macrostructure, cerebral vasoreactivity and cognitive neuroscience. Besides the significant health-related consequences of OSAS including hypertension, increased risk of cardio- and cerebrovascular events, notable neurocognitive lapses and excessive daytime somnolence are considered as potential burdens. The intermittent nocturnal hypoxia and hypercapnia which occur in OSAS are known to affect cerebral circulation and result in brain hypoperfusion. Arousal instability is then resulted from altered cyclic alternating patterns (CAPs) reflected in sleep EEG. In chronic state, some pathological loss of gray matter may be resulted from obstructive sleep apnea. This is proposed to be related to an upregulated proinflammatory state which may potentially result in apoptotic cell loss in the brain. On this basis, a pragmatic framework of the possible neural mechanisms which underpin obstructive sleep apnea-related neurocognitive decline has been discussed in this review. In addition, the impact of OSAS on cerebral autoregulation and sleep microstructure has been articulated.

Entities:  

Keywords:  Obstructive sleep apnea; cerebral autoregulation; cyclic alternating patterns; neurocognitive performance; sleep microstructure

Mesh:

Year:  2015        PMID: 25916253     DOI: 10.1142/S0219635215500144

Source DB:  PubMed          Journal:  J Integr Neurosci        ISSN: 0219-6352            Impact factor:   2.117


  1 in total

1.  Continuous positive airway pressure might not solve your cerebral autoregulation problem if you have obstructive sleep apnoea.

Authors:  Stephen Payne
Journal:  J Physiol       Date:  2016-12-01       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.